{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:48:45Z","timestamp":1781279325959,"version":"3.54.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune disease primarily mediated by acetylcholine receptor antibodies (AChR-Ab), cellular immune dependence, and complement system involvement. Since the AChR on the postsynaptic membrane is destroyed by an immune attack, sufficient endplate potential cannot be generated, resulting in the development of a synaptic transmission disorder at the neuromuscular junction and in muscle weakness. The role of the complement system in MG has been demonstrated in animal models and clinical tests, and it has been determined that complement inhibition in patients with MG can prevent disease induction and reverse its progression. Eculizumab is a humanized monoclonal antibody that inhibits the cleavage of complement protein C5 and prevents autoimmune damage; additionally, it has received subsequent approval by the Federal Drug Administration of the United States for MG treatment. However, various concerns regarding the use of eculizumab persist. In this review, we have discussed the treatment time, cost effectiveness, long-term efficacy, and tolerability of eculizumab for MG treatment. We have also summarized historical information and have presented perspectives on this new therapeutic modality.<\/jats:p>","DOI":"10.3389\/fimmu.2021.715036","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T05:04:14Z","timestamp":1628658254000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis"],"prefix":"10.3389","volume":"12","author":[{"given":"Hai","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng Po","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and Therapy of Myasthenia Gravis With Antibodies to Muscle-Specific Kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-2963.2015.03.013","article-title":"Advances in Research on the Mechanism of Myasthenia Gravis Immunology","volume":"3","author":"Li","year":"2015","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.07.011","article-title":"AChR-Specific Immunosuppressive Therapy of Myasthenia Gravis","volume":"97","author":"Luo","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"B4","article-title":"Comparison of the Efficacy of Gracilis and Glucocorticoids in the Treatment of Myasthenia Gravis","volume":"3","author":"Shen","year":"2014","journal-title":"Chin Foreign Med Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-7860.2017.04.074","article-title":"Progress in Research and Treatment of Myasthenia Gravis Antibody","volume":"4","author":"Dong","year":"2017","journal-title":"Clin Res Trad Chin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-2963.2006.03.006","article-title":"Immune Shock Plus Mechanical Ventilation to Rescue Myasthenia Gravis Crisis","volume":"3","author":"Liu","year":"2006","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(08)60171-0","article-title":"Clinical Characteristics of MuSK Antibody-Positive Myasthenia Gravis in Taiwan","volume":"107","author":"Huang","year":"2008","journal-title":"J Formos Med Assoc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-2963.2014.02.013","article-title":"Advances in Research on Myasthenia Gravis Related Antibodies","volume":"2","author":"Jing","year":"2014","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-pathol-012615-044145","article-title":"Complement Dysregulation and Disease: Insights From Contemporary Genetics","volume":"12","author":"Liszewski","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648","article-title":"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the Complement Inhibitor Eculizumab on Thromboembolism in Patients With Paroxysmal Nocturnal Hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.032","article-title":"Terminal Complement Blockade After Hematopoietic Stem Cell Transplantation is Safe Without Meningococcal Vaccination","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter Phase 3 Study of the Complement Inhibitor Eculizumab for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-6731.2012.02.003","article-title":"Review and Prospect of Pathogenesis and Treatment of Myasthenia Gravis","volume":"2","author":"Li","year":"2012","journal-title":"Chin J Mod Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune Myasthenia Gravis: Emerging Clinical and Biological Heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"B17","article-title":"Zhao Chongbo. Myasthenia Gravis and Cytokines","volume":"4","author":"Yi","year":"2014","journal-title":"Chin Clin Neurosci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and Cytokine Based Therapeutic Strategies in Myasthenia Gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical Features, Pathogenesis, and Treatment of Myasthenia Gravis: A Supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A Systematic Review of Population Based Epidemiological Studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia Gravis: A Comprehensive Review of Immune Dysregulation and Etiological Mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.34","article-title":"Muscle Autoantibodies in Myasthenia Gravis: Beyond Diagnosis","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2014-0021","article-title":"Targeting Complement System to Treat Myasthenia Gravis","volume":"25","author":"Huda","year":"2014","journal-title":"Rev Neurosci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1003-4706.2004.01.029","article-title":"Treatment of Myasthenia Gravis","volume":"12","author":"Wang","year":"2013","journal-title":"Prog Mod BioMed"},{"key":"B26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3969\/j.issn.1007-614x.2010.21.152","article-title":"Pathogenesis. Clinical Manifestations and Treatment of Myasthenia Gravis","volume":"21","author":"Cui Bo","year":"2010","journal-title":"Chin Commun Phys (Med Major)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-7768.2011.03.031","article-title":"Diagnosis and Treatment of Myasthenia Gravis","volume":"3","author":"Chen","year":"2011","journal-title":"Intern Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51327.x","article-title":"Immunosuppressive Drugs: Azathioprine in the Treatment of Myasthenia Gravis","volume":"505","author":"Matell","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/BF00314245","article-title":"Azathioprine as a Single Drug or in Combination With Steroids in the Treatment Ofmyasthenia Gravis","volume":"235","author":"Mantegazza","year":"1988","journal-title":"J Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"116734","DOI":"10.1016\/j.jns.2020.116734","article-title":"Myasthenia Gravis and Azathioprine Treatment: Adverse Events Related to Thiopurine S-Methyl-Transferase (TPMT) Polymorphisms","volume":"412","author":"Paulo","year":"2020","journal-title":"J Neurol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14500","article-title":"Changes in Serum Complements and Their Regulators in Generalized Myasthenia Gravis","volume":"28","author":"Ozawa","year":"2021","journal-title":"Eur J Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420935697","article-title":"C5a and Anti-Acetylcholine Receptor Antibody as Severity Biomarkers in Myasthenia Gravis","author":"Florencia","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of Complement Activity by Humanized Anti-C5 Antibody and Single-Chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344","article-title":"Discovery and Development of the Complement Inhibitor Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2040620719874728","DOI":"10.1177\/2040620719874728","article-title":"Ravulizumab: A Novel C5 Inhibitor for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","volume":"10","author":"Stern","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.0253-9713.2006.10.015","article-title":"Application of Intravenous Infusion of Immunoglobulin in Nervous System Diseases","volume":"10","author":"Wang","year":"2006","journal-title":"Beijing Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0376-2491.2010.39.009","article-title":"Video-Assisted Thoracoscopic Expanded Thymectomy For Myasthenia Chinese","volume":"39","author":"Chen","year":"2010","journal-title":"Chin Med J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary Thrombotic Microangiopathy in Systemic Lupus Erythematosus and Antiphospholipid Syndrome, the Role of Complement and Use of Eculizumab: Case Series and Review of Literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.125","article-title":"The Complement System as a Potential Therapeutic Target in Rheumatic Disease","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51331","article-title":"A Population-Based Study of Head Injury, Cognitive Function and Pathological Markers","volume":"8","author":"James","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B44","article-title":"Consistent Improvement With Eculizumab Across Muscle Groups in Myasthenia Gravis","volume":"7","author":"Renato","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577424","article-title":"Severe Worsening of Myasthenic Symptoms After the Eculizumab Discontinuation","volume":"349","author":"Akiyuki","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B46","doi-asserted-by":"crossref","first-page":"1756286420911784","DOI":"10.1177\/1756286420911784","article-title":"Response to Eculizumab in Patients With Myasthenia Gravis Recently Treated With Chronic IVIg: A Subgroup Analysis of REGAIN and its Open-Label Extension Study","volume":"13","author":"Jacob","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1756286420904207","DOI":"10.1177\/1756286420904207","article-title":"Suitable Indications of Eculizumab for Patients With Refractory Generalized Myasthenia Gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"B48","doi-asserted-by":"crossref","first-page":"116419","DOI":"10.1016\/j.jns.2019.08.004","article-title":"Long-Term Efficacy and Safety of Eculizumab in Japanese Patients With Generalized Myasthenia Gravis: A Subgroup Analysis of the REGAIN Open-Label Extension Study","volume":"407","author":"Murai","year":"2019","journal-title":"J Neurol Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000511957","article-title":"Eculizumab During Pregnancy in a Patient With Treatment-Refractory Myasthenia Gravis: A Case Report","volume":"13","author":"Vu","year":"2021","journal-title":"Case Rep Neurol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190464","article-title":"Retrospective Analysis of Eculizumab in Patients With Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series","volume":"7","author":"Datta","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200584","article-title":"Clinical Experience With Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis","volume":"8","author":"Katyal","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"17562864211001995","DOI":"10.1177\/17562864211001995","article-title":"Safety and Effectiveness of Eculizumab in Japanese Patients With Generalized Myasthenia Gravis: Interim Analysis of Post-Marketing Surveillance","volume":"14","author":"Murai","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical Effects of the Self-Administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1897567","article-title":"Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis","volume":"30","author":"Howard","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13083","article-title":"Development and Characterization of Novel Anti-C5 Monoclonal Antibodies Capable of Inhibiting Complement in Multiple Species","volume":"157","author":"Zelek","year":"2019","journal-title":"Immunology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.04.009","article-title":"Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-Clinical Models of Myasthenia Gravis","volume":"13","author":"Kusner","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement Deposition at the Neuromuscular Junction in Seronegative Myasthenia Gravis","volume":"139","author":"Hoffmann","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: A Review in Systemic Lupus Erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00443-w","article-title":"Monoclonal Antibody-Based Therapies for Myasthenia Gravis","volume":"34","author":"Alabbad","year":"2020","journal-title":"BioDrugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.715036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T05:04:26Z","timestamp":1628658266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.715036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2021.715036"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.715036","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"article-number":"715036"}}